Entity

Time filter

Source Type

DURHAM, NC, United States

Patent
North Carolina State University and Biomarck Pharmaceuticals, Ltd | Date: 2014-04-07

The present invention relates to methods and compounds for treating or preventing cancer. Methods and compositions provided include including inhibiting or suppressing the development, maintenance, and proliferation of cancers, including blocking or inhibiting cancer cell metastasis.


Patent
Biomarck Pharmaceuticals, Ltd | Date: 2014-11-10

Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 6 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.


Patent
Biomarck Pharmaceuticals, Ltd | Date: 2013-06-28

Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 6 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.


Grant
Agency: Department of Health and Human Services | Branch: | Program: STTR | Phase: Phase I | Award Amount: 201.50K | Year: 2014

DESCRIPTION (provided by applicant): The objective of the proposed project is to advance the development of novel peptides targeting MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) protein as platform drug molecules for the treatment of Acute Lung Injury (ALI) and its more severe form, Acute Respiratory Distress Syndrome (ARDS), thereby providing the first pharmacologic therapeutic for this condition. ALI/ARDS is a major cause of respiratory failure; worldwide, over 1 million cases occur annually, with ~ 200,000 adult and 15,000 pediatric cases per year in the U.S. This disorder is characterized by a large influx of neutrophils to the lung as part of an acute inflammatory response, injury to epithelial and endothelial cell barriers, and pulmonary edema, all of which lead to respiratory failure. Treatment options are presently limited to mechanical ventilation, a supportive therapy which still results in an in-hospital mortality rate of ~40% in the U.S., with few survivors discharged to home due t


Patent
Biomarck Pharmaceuticals, Ltd | Date: 2015-03-04

The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.

Discover hidden collaborations